Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques

Kaifi, Jussuf T.; Kunkel, Miriam; Das, Avisnata; Harouaka, Ramdane; Dicker, David T.; Li, Guangfu; Zhu, Junjia; Clawson, Gary A.; Yang, Zhaohai; Reed, Michael F.; Gusani, Niraj J.; Kimchi, Eric T.; Staveley-O’Carroll, Kevin F.; Zheng, Shan; El‐Deiry, Wafik S.

doi:10.1080/15384047.2015.1030556

Cited by 60 publications

(74 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, CellSearch detected CTCs in 22% (4/18) of samples. The higher rate of CTC detection using the FMSA compared to CellSearch was corroborated by another recent clinical study (Kaifi et al, 2015).…”

Section: Two-dimensional Microfiltration Systemssupporting

confidence: 68%

“…Constructed from parylene-C, can process WB, captures viable cells, clusters observed Kaifi et al, 2015) 3D FaCTChecker Constructed from parylene-C, captures viable cells between membrane layers Parsortix Viable cells released by reversing flow Resettable Cell Trap Pneumatically-controlled microvalves (Qin et al, 2015) Cluster Chip Triangular pillars designed for CTC clusters (Sarioglu et al, 2015) Biophysical e Inertial Focusing Cells are passively separated by size through the application of inertial forces in microfluidic devices that affect positioning within the flow channel.…”

Section: D Track-etched Isetmentioning

confidence: 99%

See 1 more Smart Citation

Circulating tumor cell technologies

2016

View full text Add to dashboard Cite

Cancer CTC capture CTC clustersImmunoaffinity enrichment A B S T R A C TCirculating tumor cells, a component of the "liquid biopsy", hold great potential to transform the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of CTCs lies in the ability to detect and isolate these rare cells using methods amenable to downstream characterization and other applications. In this review, we will provide an overview of current technologies used to detect and capture CTCs with brief insights into the workings of individual technologies. We focus on the strategies employed by different platforms and discuss the advantages of each. As our understanding of CTC biology matures, CTC technologies will need to evolve, and we discuss some of the present challenges facing the field in light of recent data encompassing epithelial-to-mesenchymal transition, tumor-initiating cells, and CTC clusters.

show abstract

Section: Two-dimensional Microfiltration Systemssupporting

confidence: 68%

Section: D Track-etched Isetmentioning

confidence: 99%

Circulating tumor cell technologies

2016

View full text Add to dashboard Cite

show abstract

“…24,25 To further address this we initiated a clinical trial on intraoperative CTC isolation during CRC lung and liver metastasectomy, comparing the CellSearch Ò system with a sizebased CTC isolation technique (ClinicalTrials.gov Identifier: NCT01722903) that demonstrated higher CTC capture efficiency intraoperatively with an innovative filter. 31 Several studies have demonstrated the clinical significance of CTC numbers as a prognostic marker when enumerated by the CellSearch Ò system in metastatic tumors of breast, colon and prostate. 12,26,27 However, CellSearch Ò is limited by the selection of EpCAMC CTCs only.…”

Section: Discussionmentioning

confidence: 99%

Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver

Kaifi¹,

Kunkel

Dicker

et al. 2015

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

Background: Metastatic spread is the most common cause of cancer-related death in colorectal cancer (CRC) patients, with the liver being the mostly affected organ. Circulating tumor cells (CTCs) are a prognostic marker in stage IV CRC. We hypothesized that tumor burden in the liver correlates with CTC quantity. Methods: Blood (7.5 ml) was prospectively collected from 24 patients with novel stage IV CRC diagnosis. Baseline EpCAMC CTCs were analyzed with the FDA-approved CellSearch Ò system. Clinicopathological data were collected, and hepatic tumor burden was determined by radiographic liver volumetry with contrast-enhanced CT scans. CRC primary tumors were immunohistochemically stained for EpCAM expression with BerEP4 monoclonal antibody. Statistical analyses were performed using 2-sample T-test, non-parametric Wilcoxon Rank-Sum test, and Fisher's exact test. Results: CTCs were detected n 17 (71%) of 24 patients. The overall mean CTC number as determined by EpCAM-based CellSearch Ò detection was 6.3 (SEM 2.9). High baseline CTC numbers (3) correlated significantly with a high tumor/liver ratio (30%), and with high serum CEA levels, as determined by two-sample T-test on log-transformed data and by Fisher's Exact test on categorical data analysis (P < 0.05). The CRC primary tumors were consistently expressing EpCAM by immunostaining. Conclusions: High tumor burden in the liver and high baseline serum CEA levels are associated with high number of baseline CTCs in stage IV CRC patients. Future studies should further investigate the biological role and expression patterns of single CTCs in cancer patients to further improve personalized treatment strategies.

show abstract

“…Response to treatment in one lung cancer patient was monitored using the NanoVelcro technology in addition to whole genome amplification and Sanger sequencing to detect relevant mutations in EGFR at time points before and after treatment with Gefitinib [16]. Consequences of metastasectomy were evaluated through CTC enumeration over multiple time points with the FMSA device in metastatic colorectal cancer patients [40]. Microfluidic technologies have also been used to illuminate biological subtleties of these cells in transit.…”

Section: Applications Of Ctc Isolation Technologiesmentioning

confidence: 99%

The incorporation of microfluidics into circulating tumor cell isolation for clinical applications

Kozminsky

Wang

Nagrath

2016

Current Opinion in Chemical Engineering

View full text Add to dashboard Cite

The second leading cause of death in the United States, cancer is at its most dangerous as it spreads to secondary locations. Cancer cells in the blood stream, or circulating tumor cells (CTCs), present an opportunity to study metastasis provided they may be extracted successfully from blood. Engineers have accelerated the development of technologies that achieve this goal based on exploiting differences between tumor cells and surrounding blood cells such as varying expression patterns of membrane proteins or physical characteristics. Collaboration with biologists and clinicians has allowed additional analysis and will lead to the use of these rare cells to their full potential in the fight against cancer.

show abstract

Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques

Cited by 60 publications

References 62 publications

Circulating tumor cell technologies

Circulating tumor cell technologies

Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver

The incorporation of microfluidics into circulating tumor cell isolation for clinical applications

Contact Info

Product

Resources

About